{"id":"NCT01302860","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease","officialTitle":"A One-year Open-label, Multicenter Trial to Assess Efficacy, Safety and Tolerability of Canakinumab (ACZ885) and the Efficacy and Safety of Childhood Vaccinations in Patients Aged 4 Years or Younger With Cryopyrin Associated Periodic Syndromes (CAPS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-11","primaryCompletion":"2014-11","completion":"2014-11","firstPosted":"2011-02-24","resultsPosted":"2015-08-18","lastUpdate":"2017-03-29"},"enrollment":17,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cryopyrin-associated Periodic Syndromes","Familial Cold Autoinflammatory Syndrome","Muckle-Wells Syndrome","Neonatal Onset Multisystem Inflammatory Disease"],"interventions":[{"type":"DRUG","name":"ACZ885","otherNames":[]}],"arms":[{"label":"Canakinumab","type":"EXPERIMENTAL"}],"summary":"This trial will assess the safety, efficacy and tolerability of ACZ885 in patients aged 4 years and younger with cryopyrin associated periodic syndromes (CAPS)","primaryOutcome":{"measure":"Percentage of Participants Aged 4 Years or Younger With at Least One Complete Response at Week 56","timeFrame":"Week 56","effectByArm":[{"arm":"Canakinumab","deltaMin":94.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Month","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":12,"countries":["Belgium","Canada","France","Germany","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":["31161734"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":17},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Pyrexia","Rhinitis","Diarrhoea"]}}